Abstract:Introduction Patients with relapsed/refractory Hodgkin lymphoma (R/R HL) experience high response rates upon anti-PD1 therapy. In these patients, the optimal duration of treatment and the risk of relapse after anti-PD1 discontinuation are unknown. Furthermore, the efficacy of anti-PD1 re-treatment in patients who relapse after anti-PD1 discontinuation remains to be determined. Here, we investigated the risk of relapse in patients who responded to anti-PD1 therapy and discontinued the treatment, as well as the efficacy of anti-PD1 re-treatment in patients who relapsed after anti-PD1 discontinuation. Methods We retrospectively analyzed patients with R/R HL who responded to anti-PD1 monotherapy (concomitant radiotherapy was permitted) and discontinued the treatment either because of unacceptable toxicity or prolonged remission (based on the clinician's decision). Patients who discontinued because of relapse/progression or underwent consolidation with allogenic stem cell transplantation [alloSCT] were not included. A random forest machine-learning algorithm was trained to predict relapse using 14 candidate biomarkers. Finally, we analyzed the outcome of patients who relapsed after anti-PD1 discontinuation and their response to anti-PD1 re-treatment. Results We included 32 patients from 13 Centers in France, Portugal and Belgium. Patients' characteristics are summarized in Table 1. At the time of anti-PD1 discontinuation, patients had received either nivolumab (N=27, 84.4%) or pembrolizumab (N=5, 12.5%) for a median duration of 14.6 (range, 0-33.5) months. Patients discontinued anti-PD1 treatment either because of prolonged remission (N=23, 71.9%) or unacceptable toxicity (N=9, 28.1%). Most patients were in CR (N=29, 90.1%) at the time of anti-PD1 discontinuation. After a median follow-up of 20.8 months (range, 0.7-47.6) from anti-PD1 discontinuation, 21 (65.6%) patients had not relapsed/progressed. All 3 patients who were in PR at the time of anti-PD1 discontinuation had relapsed. Among the 29 patients who were in CR at the time of anti-PD1 discontinuation, the estimated disease-free survival was 64.3% (CI 95, 46.6-88.7%) at 24 months (Figure 1). Three patients died: two from disease progression and one from severe GVHD while in CR. Interestingly, 4 patients remain in CR more than 3 years after anti-PD1 discontinuation although these patients had received only short courses of anti-PD1 (<6 months). One of them received a single dose of nivolumab for a relapse post-alloSCT and remains disease-free 47.6 months later. Using a testing set of 25 patients, the machine-learning algorithm predicted an increased risk of relapse at 12 months based on three main patients characteristics: the absence of complete metabolic response at the end of anti-PD1 treatment, prolonged time to achieve best overall response, and older age. Among the 11 patients who relapsed, 7 were re-treated with (the same) anti-PD1 (Figure 2). Five achieved a CR, 1 achieved a PR and one patient has not been evaluated yet (but is in clinical response). Conclusion A significant proportion of patients experience prolonged remissions after anti-PD1 discontinuation and thus might be cured. Using a machine-learning algorithm, we identified biomarkers capable of predicting the risk of relapse after anti-PD1 discontinuation. These biomarkers are currently being validated in an independent set of patients. Finally, among patients who relapse after anti-PD1 discontinuation, re-treatment with anti-PD1 appears to be efficient. Disclosures Manson: Bristol Myers Squibb: Honoraria. Brice:Takeda France: Consultancy, Honoraria; Millennium Takeda: Research Funding; BMS: Honoraria. Herbaux:Janssen: Honoraria; BMS: Honoraria; Takeda: Honoraria; Abbvie: Honoraria; Gilead: Honoraria. Silva:Abbvie Inc: Consultancy; Celgene: Consultancy; Gilead Sciences: Consultancy, Research Funding; Janssen Cilag: Consultancy; Roche: Consultancy. Stamatoulas Bastard:Celgene: Honoraria; Takeda: Consultancy. Houot:Bristol Myers Squibb: Honoraria; Merck Sharp Dohme: Honoraria.

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first‐line anti‐programmed death‐1 monotherapy: A real‐world multicentre observational cohort study

Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients

Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data

1106P International Experience of Ipilimumab and Nivolumab in Patients with Advanced Melanoma

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy

P1.16-09 Post-Progression Outcomes after Pembrolizumab in Patients with NSCLC and High PD-L1 Expression: Real-World Data from a European Cohort

Outcomes from Salvage Chemotherapy or Pembrolizumab Beyond Progression with or Without Local Ablative Therapies for Advanced Non-Small Cell Lung Cancers with PD-L1 ≥50% Who Progress on First-Line Immunotherapy: Real-World Data from a European Cohort.

Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study

Risk of Relapse after Anti-PD1 Discontinuation and Efficacy of Anti-PD1 Re-Treatment in Patients with Hodgkin Lymphoma

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

Real-World Data on Clinical Outcomes and Treatment Management of Advanced Melanoma Patients: Single-Center Study of a Tertiary Cancer Center in Switzerland

The efficacy of anti‐programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

Real-World Safety and Outcome of First-Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort ("PEMBROREAL" Study)

Early versus late response to PD-1-based immunotherapy in metastatic melanoma

Efficacy of Salvage Therapies after Failure of Adjuvant Anti-Pd-1 Monotherapy for Melanoma in the Chinese Population: a Multi-Institutional Cohort Study

Efficacy and Safety of Combined Anti-Angiogenic Chemoradiotherapy with PD-1 Monoclonal Antibody in Advanced Melanoma: A Retrospective Study.

Abstract CT009: S1512: High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma

Weekly carboplatin plus paclitaxel chemotherapy in advanced melanoma patients resistant to anti-PD-1 inhibitors: a retrospective, monocentric experience